SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: aknahow who wrote (12378)12/3/1999 10:13:00 AM
From: Cacaito  Respond to of 17367
 
George, is a question of resources, not failures. Biogen will redirect lots of resources to the development of Amevive, now that they stopped six clinical trials with Antova.

xoma has the failures and I will say even the technologies, but the lack of resources is chronic, especially with the waste on ceoperson compensation.

Just check today news on Biogen.

By the way, some around are still trying to find out about trauma failure, it is a failure, it does not work. Period.